CytomX Therapeutics, Inc. (CTMX)

NMS – Цена в реальном времени. Валюта: USD

3.88

+0.02 (0.52%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.92

+0.04 (0.98%)

До открытия: May 13, 2026, 4:00 AM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update

Search stocks

CytomX Therapeutics, Inc. (CTMX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Видео

No Data

Пресс-релизы

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update